Ingevity Corporation
NGVT
$54.57
-$0.52-0.94%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.32B | 1.35B | 1.41B | 1.48B | 1.55B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.32B | 1.35B | 1.41B | 1.48B | 1.55B |
| Cost of Revenue | 835.40M | 875.60M | 945.40M | 1.05B | 1.12B |
| Gross Profit | 489.40M | 474.70M | 461.00M | 432.10M | 431.20M |
| SG&A Expenses | 165.30M | 162.50M | 166.60M | 171.00M | 172.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 3.10M | 3.60M | 3.60M | 3.60M |
| Total Operating Expenses | 1.03B | 1.07B | 1.14B | 1.25B | 1.32B |
| Operating Income | 294.60M | 280.10M | 262.70M | 229.50M | 226.20M |
| Income Before Tax | -245.00M | -436.90M | -535.60M | -698.40M | -528.40M |
| Income Tax Expenses | -28.40M | -83.10M | -105.30M | -134.70M | -97.10M |
| Earnings from Continuing Operations | -216.60 | -353.80 | -430.30 | -563.70 | -431.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -216.60M | -353.80M | -430.30M | -563.70M | -431.30M |
| EBIT | 294.60M | 280.10M | 262.70M | 229.50M | 226.20M |
| EBITDA | 396.80M | 386.40M | 376.10M | 340.90M | 344.40M |
| EPS Basic | -5.95 | -9.74 | -11.84 | -15.53 | -11.88 |
| Normalized Basic EPS | 3.55 | 2.84 | 2.09 | 1.57 | 1.50 |
| EPS Diluted | -5.96 | -9.75 | -11.85 | -15.54 | -11.90 |
| Normalized Diluted EPS | 3.54 | 2.83 | 2.09 | 1.57 | 1.50 |
| Average Basic Shares Outstanding | 145.49M | 145.36M | 145.24M | 145.14M | 145.02M |
| Average Diluted Shares Outstanding | 146.07M | 145.94M | 145.54M | 145.14M | 145.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |